Search
forLearn
5 / 801 resultslearn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn Hair Multiplication
extract, clone, and reinsert your own hair cells
learn Minoxidil
An essential vasodilator with some anti-androgenic effects, has excellent safety record
learn Nanoxidil
Research
5 / 1000+ results
research Oleic Acid Nanovesicles of Minoxidil for Enhanced Follicular Delivery
Oleic acid nanovesicles improve minoxidil absorption in hair follicles for alopecia treatment.
research Synthesis and characterization of inclusion complex of the vasodilator drug minoxidil with β-cyclodextrin
Minoxidil mixed with β-cyclodextrin improves solubility and gradual release.
research "Preparation and Physicochemical Characterization of Topical Niosomal Formulation of Minoxidil and Tretinoin"
A new hair loss treatment was created using minoxidil and tretinoin in stable niosomes, which effectively released the drugs over time.
research Development and Characterization of Film Forming Spray of 5% Minoxidil for Baldness Due to Androgenetic Alopecia
A 5% minoxidil spray could effectively treat male baldness with fewer side effects and better patient comfort.
research Vesicular Carriers for Improved Oral Anticoagulation Competence of Rivaroxaban: In Vitro and In Vivo Investigation
Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
Community Join
5 / 1000+ resultscommunity Will you guys be trying the time-release oral minoxidil when it comes out?
People are discussing the potential benefits and drawbacks of a new time-release oral minoxidil (VDPHL01) for hair loss, with considerations about its cost, efficacy, and side effects compared to current treatments like 2.5mg doses and topical applications. Some users express interest in trying it if it proves effective and affordable, while others are cautious due to potential side effects or are satisfied with their current regimen.
community 6 months before and after pics: VDPHL01 (oral minoxidil)
A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
community Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!)
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.